Inadequate Response in Major Depressive Disorder: Optimizing Outcomes with Adjunctive Antipsychotic Therapy
Major depressive disorder has a major impact on ability to function and has a negative impact on quality of life. MDD is a leading cause of disability throughout the world and is a major contributor to the overall global burden of disease.
Treatment outcomes can be poor, with less than half of those treated achieving remission. A failure to regain pre-morbid level of function is common and impacts both the person and their love ones.
This program includes two case-based modules, the first of which will review treatment initiation and optimization in MDD based on the CANMAT guidelines, with a focus on the advantages and disadvantages of different treatment alternatives.The second case-based module will review the evidence supporting different management options for optimizing treatment of MDD and will review the atypical antipsychotic treatment options for adjunctive therapy in MDD.
This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 1.25 CEU(s). CCCEP File Number: 1066-2020-3088-I-P
Serge Lessard, MD, FRCPC
Ajit Johal, BSP RPh BCPP CDE CTH
Upon completion of this learning program participants will be better able to:
- Identify patients with inadequate response to treatment for major depressive disorder.
- Distinguish the pharmacological approaches for managing inadequate response to treatment for major depressive disorder.
- Differentiate the antipsychotic treatment options for adjunctive therapy in major depressive disorder.
- Develop an approach to counselling patients about adjunctive therapy in major depressive disorder.